Robert Barrow - Jun 25, 2025 Form 4 Insider Report for Mind Medicine (MindMed) Inc. (MNMD)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow
Stock symbol
MNMD
Transactions as of
Jun 25, 2025
Transactions value $
-$180,139
Form type
4
Date filed
6/26/2025, 04:30 PM
Previous filing
Mar 26, 2025
Next filing
Sep 26, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barrow Robert Chief Executive Officer, Director C/O MIND MEDICINE (MINDMED) INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK /s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow 2025-06-26 0001897557

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNMD Common Shares Sale -$180K -26.5K -3.09% $6.80 830K Jun 25, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022.
F2 The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.